Medically reviewed by Lindsay Cook, PharmDCalcitonin gene-related peptide (CGRP) inhibitors are now considered a first-line ...

Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. Log out ...

Preventing migraine chronification and medication overuse headache requires decreasing the number of migraine attacks and ...

Pfizer’s Vydura has become the first oral CGRP antagonist recommended for routine use by the NHS to prevent episodic migraine attacks, after being rejected earlier this year as an acute treatment.

Mind+ Neurology is advancing medical research and offering hope to patients living with migraine. Mind+ is an authorized site for a new Episodic Migraine clinical trial.

Merck has announced that the antagonist of the calcitonin gene-related peptide (CGRP) receptor telcagepant has met the primary end points in two Phase III trials to treat migraine, which is ...

No new safety signals emerged after concomitant atogepant plus ubrogepant in patients with atogepant-refractory episodic migraine.

第三款创新鼻喷剂疗法来了，目前赛道是国外新药的竞技舞台（随着同靶点新药剧增，可能面临价格战），国内药企则鲜少研发。图源：pixabay关于偏头痛Guide ...

New research identifies shared genetic factors between migraine and several gastrointestinal disorders, offering insights ...

The compounds are oral small molecules based on three distinct mechanistic platforms: calcitonin gene-related peptide (CGRP) receptor antagonists, glutamate modulators, and myeloperoxidase inhibitors.